在1,2,3-triazoles-based IIIM(S) -RS98中介肺癌细胞中发生亡的机制方法
Rigzin Dolkar1,2, Gourav Paudwal1,2, Davinder Singh3,2
1Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India.
The AAPS journal
|February 3, 2025
概括
一种新的1,2,3三醇化合物,IIIM(S) -RS98,显示出对肺癌的显著潜力. 它有效诱导亡并抑制癌细胞生长,为肺癌治疗提供了一个有前途的新途径.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 肺癌是全球癌症相关死亡的主要原因之一.
- 对于抗击肺癌的新型治疗药物有着至关重要的需求.
- 1,2,3三醇衍生物显示出作为抗癌药物的前景.
研究的目的:
- 为了评估一种新的1,2,3三醇化合物的抗肺癌疗效,IIIM(S) -RS98.
- 研究IIIM(S) -RS98对各种癌症细胞系的细胞毒性潜力和作用机制.
主要方法:
- 在多个癌症细胞系和正常细胞的体外细胞毒性测定.
- 流细胞计测试以评估细胞亡,线粒体膜潜力,ROS,氧化和细胞循环.
- 西方涂抹用于分析apoptotic和信号通路中的关键蛋白质.
- 分子对接以预测与标蛋白的相互作用.
主要成果:
- IIIM(S) -RS98对A549肺癌细胞表现出强烈的细胞毒性,其选择性指数为8.16.
- 该化合物诱导了亡,G1细胞周期停止,并抑制了细胞迁移和克隆性潜力.
- IIIM(S) -RS98调节PI3K/Akt通路,通过酶激活导致细胞亡,并改变了Bcl-2/Bax的表达.
结论:
- IIIM(S) -RS98通过多种机制显示出显著的抗肺癌活性,包括诱导亡.
- 该化合物的向关键癌症途径的能力表明它有可能成为肺癌的新型治疗剂.
- 对IIIM(S) -RS98进行进一步的研究是有必要的,以便其作为肺癌治疗的发展.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...